Affinage

CDCP1

CUB domain-containing protein 1 · UniProt Q9H5V8

Length
836 aa
Mass
92.9 kDa
Annotated
2026-04-28
100 papers in source corpus 38 papers cited in narrative 38 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CDCP1 is a type I transmembrane glycoprotein that functions as a signaling scaffold, integrating extracellular proteolytic cues with intracellular kinase cascades to regulate cell survival, migration, invasion, and immune cell interactions. Full-length CDCP1 (135 kDa) is phosphorylated at Y734 (and Y743/Y762) by Src family kinases; proteolytic cleavage at R368/K369 by uPA and plasmin generates a membrane-retained 70 kDa fragment that becomes hyperphosphorylated, recruits PKCδ via its C2 domain, homodimerizes through its CUB2 domain, and complexes with activated β1 integrin to drive FAK/PI3K/Akt survival signaling and suppress anoikis (PMID:20551327, PMID:22179830, PMID:33859413, PMID:26876198, PMID:23208492). Beyond this core axis, CDCP1 enhances HER2–SRC interaction and trastuzumab resistance, promotes Wnt/β-catenin nuclear translocation, binds TGF-β1 as a co-receptor to amplify Smad2 signaling independently of Src/PKCδ, suppresses ACSL activity to redirect fatty acid metabolism toward oxidation, and serves as a ligand for the T-cell receptor CD6 to modulate immune barrier permeability and autoimmune inflammation (PMID:25892239, PMID:31471585, PMID:31302030, PMID:28739932, PMID:28760953, PMID:35951427). CDCP1 protein levels are controlled post-translationally by palmitoylation-dependent constitutive proteasomal turnover counteracted by EGF/EGFR signaling, by FBXL14-mediated ubiquitination, and transcriptionally by HIF-2α, Ras/ERK, and BRD4/CBP-p300, while its mRNA translation is enhanced by METTL3-dependent m6A modification read by YTHDF1 (PMID:24681947, PMID:29973690, PMID:23378636, PMID:24939643, PMID:35513563, PMID:30796352).

Mechanistic history

Synthesis pass · year-by-year structured walk · 25 steps
  1. 2003 High

    Establishing that CDCP1 is a cell-surface transmembrane glycoprotein phosphorylated by Src family kinases defined its identity as a signaling-competent receptor-like molecule.

    Evidence Immunopurification, anti-phosphotyrosine western blot, and selective Src kinase inhibitor studies in cancer cells

    PMID:12660814

    Open questions at the time
    • Specific tyrosine residues not identified
    • Cleavage biology unknown
    • Downstream effectors uncharacterized
  2. 2008 Medium

    Identifying CDCP1 clustering in lipid raft/tetraspanin-enriched microdomains and its scaffolding of SFK and PKCδ at Y734 established it as a transmembrane signaling platform rather than a simple substrate.

    Evidence Detergent-resistant membrane fractionation and immunofluorescence co-localization in epithelial cells

    PMID:18269919

    Open questions at the time
    • Single-lab observation without reciprocal validation of microdomain composition
    • Functional consequence of raft localization not tested in vivo
  3. 2010 High

    Mapping the cleavage site (R368/K369) and showing that proteolysis generates a hyperphosphorylated 70 kDa fragment that recruits Src and PKCδ resolved how CDCP1 switches from a latent to an active signaling state.

    Evidence N-terminal sequencing, site-directed mutagenesis of cleavage sites, protease inhibitor panels, mass spectrometry

    PMID:20551327

    Open questions at the time
    • Identity of the physiologically relevant protease(s) in vivo not established
    • Stoichiometry of Src/PKCδ recruitment unknown
  4. 2011 High

    Demonstrating that Y734 phosphorylation is essential for Src activation, metastasis, and competitive SFK substrate-switching away from FAK-Y861 established Y734 as the critical regulatory site and positioned CDCP1 as a FAK-competing scaffold.

    Evidence Y734F mutagenesis, pharmacological Src inhibition (PP2, dasatinib), 3D Matrigel culture, in vivo metastasis assays, reciprocal phosphorylation analysis in multiple cell types

    PMID:21220330 PMID:21994943

    Open questions at the time
    • How cellular context determines the FAK-vs-CDCP1 substrate switch is not defined
    • Role of Y743 and Y762 in non-transformation phenotypes unclear
  5. 2011 High

    Showing that plasmin-mediated CDCP1 cleavage in vivo triggers Src→PKCδ→Akt survival signaling and that blocking cleavage induces apoptosis and reduces metastasis established proteolysis as the critical activating event for the pro-survival cascade.

    Evidence Plasminogen-KO mice with plasmin rescue, cleavage-site mutants, antibody blockade, aprotinin, western blot for phospho-Src/PKCδ/Akt/PARP1

    PMID:22179830

    Open questions at the time
    • Contribution of other serine proteases in different tissue contexts unknown
    • Whether cleavage is required for all CDCP1 functions (e.g. Wnt, TGF-β) not tested
  6. 2012 High

    Discovery that cleaved CDCP1 forms a complex with activated β1 integrin to induce FAK/PI3K/Akt signaling and that blocking this complex suppresses invasion and metastasis connected CDCP1 cleavage to integrin-mediated stromal invasion.

    Evidence Reciprocal Co-IP in vitro and in live animals, β1 integrin shRNA, cleavage-blocking antibody 10-D7, pharmacological FAK/PI3K inhibitors, in vivo intravasation models

    PMID:23208492

    Open questions at the time
    • Whether CDCP1–β1 integrin interaction is direct or bridged by an adaptor not resolved
    • Integrin activation state specificity not fully mapped
  7. 2012 High

    Establishing that CDCP1 localizes to caveolin-1-containing vesicles and is required for MT1-MMP trafficking to invadopodia extended its function to protease-dependent ECM degradation and invasion beyond intracellular signaling.

    Evidence Co-IP of CDCP1 and MT1-MMP, lipid raft fractionation, siRNA knockdown, ECM degradation and Matrigel invasion assays in breast cancer and melanoma cells

    PMID:23439492

    Open questions at the time
    • Direct binding between CDCP1 and MT1-MMP not confirmed
    • Mechanism of CDCP1-dependent trafficking of MT1-MMP to invadopodia unknown
  8. 2012 High

    Systematic mutagenesis showed all three intracellular tyrosines (Y734, Y743, Y762) and the palmitoylation motif (C689,690) are required for Src/CDCP1-dependent cell transformation, while Src SH2 domain binding to CDCP1 is dispensable, clarifying the structural determinants of oncogenic signaling.

    Evidence Retroviral co-expression in NIH3T3, focus formation assay with systematic point mutants of CDCP1 tyrosines and palmitoylation sites, Src domain mutants

    PMID:23300860

    Open questions at the time
    • Structural basis of Src recruitment independent of SH2 not resolved
    • How palmitoylation influences membrane localization vs. stability not dissected
  9. 2013 High

    Identifying HIF-2α (not HIF-1α) as a transcriptional inducer of CDCP1 under hypoxia revealed how the tumor microenvironment upregulates CDCP1 signaling.

    Evidence Isoform-specific shRNA knockdown of HIF-2α vs HIF-1α, HIF-2α overexpression, xenograft tumor growth with CDCP1 expression analysis

    PMID:23378636

    Open questions at the time
    • Direct HIF-2α binding to the CDCP1 promoter not demonstrated by ChIP
    • Other hypoxia-responsive regulators not excluded
  10. 2014 High

    Demonstrating that CDCP1 undergoes constitutive palmitoylation-dependent proteasomal degradation, which is counteracted by EGF/EGFR signaling that promotes CDCP1 recycling, established a post-translational regulatory circuit linking growth factor signaling to CDCP1 surface availability.

    Evidence Palmitoylation-site mutagenesis, cycloheximide chase, proteasome inhibitors, EGF treatment, surface biotinylation, migration assays

    PMID:24681947

    Open questions at the time
    • Palmitoyltransferase(s) responsible not identified
    • How EGFR signaling specifically blocks palmitoylation-dependent degradation not defined
  11. 2014 High

    Placing CDCP1 downstream of oncogenic Ras/ERK signaling and showing its requirement for Ras-mediated anoikis resistance and MMP activation established CDCP1 as a critical effector node in the Ras pathway.

    Evidence Activated Ras expression with CDCP1 knockdown and Src inhibitors; anoikis, migration, invasion, and MMP activity assays

    PMID:24939643

    Open questions at the time
    • Whether Ras directly regulates CDCP1 transcription or acts through intermediary transcription factors not fully resolved
  12. 2015 High

    Discovery that CDCP1 binds HER2 through its intracellular domain and promotes HER2–SRC interaction, leading to trastuzumab resistance, established CDCP1 as a modifier of receptor tyrosine kinase drug sensitivity.

    Evidence Co-IP with domain truncation mapping, cell migration and transformation assays, in vivo tumor formation, trastuzumab resistance readouts

    PMID:25892239

    Open questions at the time
    • Structural basis of the CDCP1–HER2 intracellular interaction not defined
    • Whether CDCP1 modulates other HER family members not tested
  13. 2016 High

    Showing that only cleaved CDCP1 homodimerizes through the CUB2 ectodomain and that dimerization drives PKCδ/ERK/p38 phosphorylation and migration resolved the question of how proteolysis creates a dimerization-competent active species.

    Evidence Overexpression of full-length vs cleaved CDCP1, recombinant ECC competitive inhibitor blocking dimerization, western blot for downstream kinases, 3D invasion assays

    PMID:26876198

    Open questions at the time
    • Direct structural evidence for CUB2-mediated dimer interface lacking
    • Whether dimerization is required for all downstream pathways (e.g. TGF-β, integrin) not tested
  14. 2017 High

    Identification of CDCP1 as a ligand for CD6 and demonstration that CD318-KO mice are protected from autoimmune encephalomyelitis revealed an unexpected immune regulatory function for CDCP1 beyond cancer.

    Evidence CD318-KO mice in EAE model, T-cell chemotaxis with soluble CD318, CD6-dependent T-cell adhesion to synovial fibroblasts

    PMID:28760953

    Open questions at the time
    • Binding affinity and stoichiometry of CDCP1–CD6 interaction not quantified
    • Whether CDCP1 cleavage modulates CD6 binding not examined
  15. 2017 High

    Discovering that CDCP1 suppresses ACSL activity to promote fatty acid oxidation and deplete lipid droplets uncovered a metabolic regulatory function distinct from its kinase-scaffolding role.

    Evidence CDCP1 knockdown/overexpression, ACSL enzymatic activity assays, CARS/TPEF lipid droplet imaging, ACSL3 co-knockdown rescue, in vivo TNBC metastasis models

    PMID:28739932

    Open questions at the time
    • Mechanism of ACSL inhibition (direct binding vs indirect) not defined
    • Which ACSL isoform(s) beyond ACSL3 are involved not fully tested
  16. 2018 High

    Identifying FBXL14 as a direct E3 ubiquitin ligase for CDCP1, controlled by miR-17/20a, established a ubiquitin-proteasome degradation axis regulating CDCP1 protein levels.

    Evidence Co-IP of FBXL14 and CDCP1, ubiquitination assays, proteasome inhibitors, miR-17/20a transfection, breast cancer metastasis assays

    PMID:29973690

    Open questions at the time
    • Specific lysine residues ubiquitinated on CDCP1 not mapped
    • Relationship between FBXL14 and palmitoylation-dependent degradation not clarified
  17. 2018 High

    Elucidating that CDCP1 loss disrupts CDK5 activity via a SRC→CDK5R1-pY234→PKCδ→CDK5-pT77 cascade, leading to loss of β1-integrin inside-out activation, connected CDCP1 scaffolding to cell adhesion regulation through CDK5.

    Evidence CDK5-T77 and CDK5R1-Y234 phosphorylation-site mutagenesis, CDK5 kinase activity assays, Co-IP of CDK5/CDK5R1, adhesion/migration assays in prostate cancer cells

    PMID:29511352

    Open questions at the time
    • Whether this CDK5 mechanism operates in cell types beyond prostate cancer not known
    • Structural basis of PKCδ-mediated CDK5 phosphorylation at T77 not resolved
  18. 2019 High

    Demonstrating that CDCP1 directly binds TGF-β1 via CUB domains and amplifies Smad2 signaling independently of Src/PKCδ established CDCP1 as a TGF-β co-receptor with a signaling output distinct from its canonical kinase scaffold function.

    Evidence BIAcore SPR binding assays, TGF-β1/BMP reporter assays, phospho-Smad2 western blot, epistasis with Src/PKCδ inhibitors and Smad2/TGFRI knockdown

    PMID:31302030

    Open questions at the time
    • Binding interface between CUB domains and TGF-β1 not structurally resolved
    • Physiological relevance of CDCP1–TGF-β1 interaction in vivo not tested
  19. 2019 High

    Showing that CDCP1 promotes nuclear translocation of β-catenin and E-cadherin to activate Wnt target genes revealed CDCP1 as a regulator of Wnt/β-catenin signaling in colorectal cancer.

    Evidence Cell fractionation, Co-IP, confocal microscopy, IHC of patient samples, CDCP1 loss-of-function in vitro and in vivo

    PMID:31471585

    Open questions at the time
    • Mechanism by which CDCP1 facilitates β-catenin nuclear entry not defined
    • Whether this function depends on CDCP1 cleavage or Y734 phosphorylation not tested
  20. 2019 High

    METTL3-dependent m6A modification of CDCP1 mRNA read by YTHDF1 enhances CDCP1 translation, adding an epitranscriptomic regulatory layer to CDCP1 expression control.

    Evidence m6A profiling, METTL3/ALKBH5 knockdown, YTHDF1 RIP, luciferase/translation reporters, bladder cancer growth assays

    PMID:30796352

    Open questions at the time
    • Specific m6A sites in CDCP1 3'-UTR not mapped at nucleotide resolution
    • Whether this regulation operates broadly across tissues not tested
  21. 2021 High

    Identification of uPA as the master protease for CDCP1 cleavage, acting both directly and via plasmin activation, resolved the long-standing question of which protease is physiologically dominant.

    Evidence Substrate-biased activity-based probe (sbABP) for protease capture, in vitro cleavage validation, in vivo metastasis models, patient co-expression analysis

    PMID:33859413

    Open questions at the time
    • Tissue-specific contributions of alternative proteases (e.g., matriptase) not excluded
    • Whether uPA inhibition is sufficient to fully block CDCP1 cleavage in all contexts not tested
  22. 2021 High

    Demonstrating that CDCP1 on dendritic cells regulates IL-6 via Syk-MAPK signaling and that CDCP1-KO mice are protected from Kawasaki-like vasculitis expanded CDCP1 function to innate immune signaling.

    Evidence CDCP1-KO mice, DC-specific expression, CAWS stimulation, IL-6 ELISA, Syk-MAPK western blot

    PMID:34099547

    Open questions at the time
    • How CDCP1 activates Syk on DCs (direct or via co-receptor) not resolved
    • CDCP1 cleavage status on DCs not characterized
  23. 2021 High

    Showing that CDCP1 recruits Src into lipid rafts to activate Met-STAT3 signaling and that CDCP1 ablation impairs compensatory renal growth after nephrectomy revealed a physiological non-cancer role for CDCP1 in organ homeostasis.

    Evidence CDCP1 siRNA/ablation, lipid raft fractionation, Co-IP of Src/STAT3/Met, unilateral nephrectomy in CDCP1-ablated mice

    PMID:33574034

    Open questions at the time
    • Whether CDCP1 directly binds Met or acts solely through Src scaffolding not determined
    • Long-term renal consequences of CDCP1 loss not followed
  24. 2022 High

    Structural and biophysical characterization showing that cleaved CDCP1 fragments remain tightly associated with minimal conformational change enabled development of neoepitope-specific therapeutic antibodies distinguishing cleaved from uncleaved forms.

    Evidence Differential phage display, biophysical characterization of cleaved vs uncleaved CDCP1, ADC/radionuclide/BiTE functional studies, syngeneic pancreatic tumor model

    PMID:35166238

    Open questions at the time
    • High-resolution atomic structure of cleaved CDCP1 not yet available
    • Whether neoepitope accessibility varies across tumor types not assessed
  25. 2022 High

    Mapping the CDCP1→SRC→ARHGEF7→RAC1 pathway downstream of HGF/Met showed how CDCP1 connects receptor tyrosine kinase activation to Rho GTPase-driven lamellipodia and invasion.

    Evidence Epistasis with CDCP1 and ARHGEF7 knockdowns, Rac1 activation assays, immunofluorescence co-localization, migration/invasion assays

    PMID:35085554

    Open questions at the time
    • Whether CDCP1 directly binds ARHGEF7 or acts solely through SRC not resolved
    • Contribution of other GEFs not excluded

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the high-resolution atomic structure of CDCP1 (both full-length and cleaved forms), the mechanism by which CDCP1 inhibits ACSL activity, the structural basis of CUB2-mediated homodimerization, and how CDCP1 coordinates its diverse signaling outputs (Src/PKCδ, Wnt, TGF-β, Syk) in a context-dependent manner.
  • No high-resolution structure available
  • ACSL inhibition mechanism (direct vs indirect) unresolved
  • Context-dependent pathway selection logic unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 6 GO:0048018 receptor ligand activity 2 GO:0098772 molecular function regulator activity 2
Localization
GO:0005886 plasma membrane 6 GO:0031410 cytoplasmic vesicle 2
Pathway
R-HSA-162582 Signal Transduction 14 R-HSA-168256 Immune System 3 R-HSA-392499 Metabolism of proteins 2 R-HSA-1430728 Metabolism 1
Partners
CD6ERBB2FBXL14ITGB1MMP14PRKCДPTPN11SRC

Evidence

Reading pass · 38 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 CDCP1 (SIMA135) is a cell surface type I transmembrane glycoprotein that is tyrosine phosphorylated, with phosphorylation mediated by a Src family kinase member, as demonstrated by selective Src kinase inhibitor studies and anti-phosphotyrosine western blot analysis. Immunopurification, western blot with anti-phosphotyrosine antibody, selective kinase inhibitor studies, immunocytochemistry Oncogene High 12660814
2010 Full-length 135 kDa CDCP1 is cleaved by serine proteases (including matriptase) at Arg-368 and Lys-369, generating a membrane-retained 70 kDa C-terminal fragment and a shed 65 kDa N-terminal ectodomain; proteolytic cleavage induces tyrosine phosphorylation of the 70 kDa fragment and recruitment of Src and PKCδ to this fragment. N-terminal sequencing of immunopurified fragments, detailed mutagenesis of cleavage sites, panel of protease inhibitors, western blot, mass spectrometry The Journal of biological chemistry High 20551327
2011 Proteolytic cleavage of CDCP1 by plasmin in vivo triggers a survival signaling cascade involving Src-mediated phosphorylation of the 70 kDa membrane-retained CDCP1 fragment, recruitment of PKCδ, and activation of Akt, which suppresses PARP1-mediated apoptosis; inhibiting cleavage (by antibody, serine protease inhibitors, or genetic mutation of the cleavage site) abolishes this signaling and induces apoptosis and reduces metastatic colonization. In vivo tumor models, antibody blockade, serine protease inhibitors (aprotinin), cleavage-site genetic mutagenesis, plasminogen-KO mice with plasmin rescue, western blot for phospho-Src/PKCδ/Akt/PARP1 Oncogene High 22179830
2011 CDCP1 overexpression activates Src family kinases, and its pro-metastatic activity requires CDCP1 tyrosine 734 (Y734F mutation abolishes Src activation, 3D dispersive growth in vitro, and in vivo metastasis enhancement). Stable overexpression, site-directed mutagenesis (Y734F), pharmacological Src inhibitors (PP2, dasatinib), 3D Matrigel culture, in vivo metastasis assay Proceedings of the National Academy of Sciences of the United States of America High 21220330
2011 CDCP1 acts as a scaffold that competes with FAK-Y861 as an SFK substrate; stable CDCP1 expression causes SFK substrate switching from FAK-Y861 to CDCP1-Y734, dependent on CDCP1 expression level and specifically on Y734 but not Y743 or Y762; FAK does not form a trimeric complex with Src and CDCP1. Stable CDCP1 expression in HeLa cells, CDCP1 phospho-site mutagenesis, western blot for p-FAK-Y861 and p-CDCP1-Y734, CDCP1 siRNA knockdown in colon cancer lines The Journal of biological chemistry High 21994943
2012 In vivo cleaved (70 kDa) CDCP1 forms a complex with activated (inside-out) β1 integrin; this complex induces FAK/PI3K/Akt phosphorylation signaling; blocking this complex (by cleavage-blocking antibody 10-D7, aprotinin, or β1 integrin shRNA) reduces FAK/Akt phosphorylation, stromal invasion, and spontaneous metastasis. Co-immunoprecipitation in cell cultures and live animals, pharmacological FAK/PI3K inhibitors, shRNA knockdown of β1 integrin, cleavage-blocking monoclonal antibody, in vivo tumor intravasation models Oncogene High 23208492
2012 CDCP1 localizes to caveolin-1-containing vesicular structures and lipid rafts, co-immunoprecipitates with MT1-MMP, and is required for trafficking of MT1-MMP to invadopodia and for MT1-MMP-dependent ECM degradation and Matrigel invasion of breast cancer and melanoma cells. Co-immunoprecipitation of CDCP1 and MT1-MMP, Triton X-100 lipid raft fractionation, siRNA knockdown, immunofluorescence localization to invadopodia, ECM degradation assays, Matrigel invasion assays Molecular cancer research : MCR High 23439492
2012 CDCP1 is phosphorylated by Src family kinases and the phosphorylated form recruits PKCδ through PKCδ's C2 domain; this interaction promotes anchorage-independent survival signaling; antibody activation of CDCP1 induces rapid tyrosine phosphorylation by Src, requires CDCP1 bivalent clustering/dimerization, translocates CDCP1 to Triton X-100-insoluble membrane fractions, and prolonged treatment induces Src-dependent, proteasome-mediated CDCP1 internalization and degradation. Focus formation assays with NIH3T3 cells co-overexpressing Src and CDCP1, antibody treatment, Triton X-100 fractionation, proteasome inhibitors, xenograft models with western blot Molecular oncology High 24055141
2008 CDCP1/Gp140 clusters in epithelial cell-cell contacts and assembles membrane microdomains (lipid rafts/TEMs) that recruit and activate SFK; active SFKs then phosphorylate CDCP1 at Y734 and also phosphorylate PKCδ, with CDCP1 acting as a transmembrane scaffold for these kinases; outside-in signals through extracellular CUB domains initiate this process. Detergent-resistant membrane fractionation, immunofluorescence co-localization, phosphorylation analysis of Y734 Biochimica et biophysica acta Medium 18269919
2013 HIF-2α (but not HIF-1α) transcriptionally induces CDCP1 expression and tyrosine phosphorylation under hypoxic conditions; shRNA knockdown of CDCP1 impairs cancer cell migration under hypoxia; overexpression of HIF-2α promotes xenograft tumor growth with enhanced CDCP1 expression and tyrosine phosphorylation. shRNA knockdown of HIF-2α and HIF-1α, HIF-2α overexpression, cell migration assays, xenograft tumor growth, western blot Proceedings of the National Academy of Sciences of the United States of America High 23378636
2014 Under basal conditions, CDCP1 constitutively internalizes from the cell surface and undergoes palmitoylation-dependent proteasomal degradation (palmitoylated at one or more of its four cytoplasmic cysteines); EGF/EGFR activation inhibits this degradation, promoting CDCP1 recycling to the cell surface and increased cell migration. Cycloheximide chase, palmitoylation-site mutagenesis of cytoplasmic cysteines, proteasome inhibitors, EGF treatment, cell surface biotinylation, migration assays Oncogene High 24681947
2014 Oncogenic Ras/ERK signaling transcriptionally induces CDCP1 expression; CDCP1 is required for Ras-mediated anoikis resistance, migration, and invasion; CDCP1 knockdown or inhibition of CDCP1 phosphorylation abrogates these Ras-induced phenotypes; CDCP1 mediates activation of MMP2 and secretion of MMP9 downstream of Ras. Activated Ras expression, CDCP1 knockdown/Src inhibitor treatment, anoikis assays, migration/invasion assays, MMP2/MMP9 activity assays Molecular cancer research : MCR High 24939643
2015 CDCP1 binds to HER2 through its intracellular domain and increases HER2's interaction with c-SRC, leading to enhanced HER2 activation, downstream signaling, and trastuzumab resistance in breast cancer cells. Co-immunoprecipitation of CDCP1 with HER2 and SRC, domain truncation mapping, cell migration/transformation assays, in vivo tumor formation, trastuzumab resistance assays Cell reports High 25892239
2015 SHP2 tyrosine phosphatase directly interacts with CDCP1 intracellular domain through residues Y734 and Y743; SHP2 knockdown increases CDCP1 phosphorylation and impairs antibody-mediated CDCP1 internalization, indicating SHP2 counteracts SFK-mediated CDCP1 phosphorylation and regulates CDCP1 cell surface availability. Co-immunoprecipitation, affinity precipitation, CDCP1 point mutants (Y734, Y743), SHP2 shRNA knockdown, flow cytometry for surface CDCP1 PloS one Medium 25876044
2016 Only cleaved CDCP1 (cCDCP1), not full-length CDCP1, is capable of homodimerization through its ectodomain; cCDCP1 homodimerization drives phosphorylation of PKCδ, ERK1/2, and p38 MAPK and induces cell migration; the extracellular portion of cleaved CDCP1 (ECC) blocks dimerization, inhibits PKCδ phosphorylation and migration, and reduces TNBC invasiveness. Overexpression of flCDCP1 vs. cCDCP1 in HEK293T, ECC competitive inhibitor, western blot for phospho-PKCδ/ERK1/2/p38, migration assays, 3D culture invasion/proliferation/apoptosis assays Oncogene High 26876198
2017 CDCP1 inhibits acyl-CoA synthetase ligase (ACSL) activity and promotes fatty acid oxidation (FAO) in mitochondria, depleting cytoplasmic lipid droplets; CDCP1 knockdown increases lipid droplet abundance and reduces TNBC migration (rescued by ACSL inhibitor Triacsin C or ACSL3 co-knockdown); in vivo blocking of CDCP1 increases lipid droplet abundance and decreases metastasis. CDCP1 knockdown/overexpression, ACSL activity assays, coherent anti-Stokes Raman scattering microscopy, two-photon excited fluorescence microscopy, Triacsin C treatment, ACSL3 co-knockdown, animal models of TNBC Proceedings of the National Academy of Sciences of the United States of America High 28739932
2017 CD318 (CDCP1) is a ligand for CD6; CD318-KO mice are protected in experimental autoimmune encephalomyelitis (similar to CD6-KO mice); soluble CD318 is chemoattractive to T cells and CD318 participates in CD6-dependent adhesion of T cells to synovial fibroblasts. CD318-KO mice in EAU model, T cell adhesion assays, chemotaxis assays with soluble CD318, identification of antigen recognized by mAb 3A11 as CD318 Proceedings of the National Academy of Sciences of the United States of America High 28760953
2018 FBXL14 E3 ubiquitin ligase directly binds CDCP1, facilitates its ubiquitination and proteasomal degradation, suppressing CDCP1 protein stability and breast cancer metastasis; miR-17/20a controls FBXL14 expression, placing it upstream of CDCP1 regulation. Co-immunoprecipitation of FBXL14 and CDCP1, ubiquitination assays, proteasome inhibitor treatment, miR-17/20a transfection, breast cancer metastasis functional assays Oncogene High 29973690
2018 Loss of CDCP1 in prostate cancer cells reduces CDK5 kinase activity by promoting SRC-mediated phosphorylation of CDK5R1/p35 at Y234, which creates a binding site for the C2 domain of PKCδ, leading to PKCδ phosphorylation of CDK5 at T77, dissociation of the CDK5/CDK5R1 complex, loss of CDK5 activity, and consequent loss of inside-out activation of β1-integrin. CDCP1 silencing, CDK5-T77 and CDK5R1-Y234 phosphorylation-site mutagenesis, Co-IP of CDK5/CDK5R1 complex, CDK5 kinase activity assays, cell adhesion/migration assays Oncogene High 29511352
2019 METTL3 and the m6A reader YTHDF1 promote translation of CDCP1 mRNA by recognizing m6A residues in the CDCP1 3'-UTR; ALKBH5 demethylase counteracts this; the METTL3-m6A-CDCP1 axis promotes bladder cancer cell growth and transformation. m6A profiling, METTL3/ALKBH5 knockdown, YTHDF1 RIP assays, m6A-seq, luciferase/translation reporter assays, in vitro and in vivo cancer growth assays Oncogene High 30796352
2019 CDCP1 directly binds TGF-β1 and BMP4 via its CUB domains (measured by BIAcore surface plasmon resonance); CDCP1 enhances TGF-β1 signaling (reporter activity and phospho-Smad2 levels) in a manner dependent on Smad2 and TGFRI, but independent of Src or PKCδ; CDCP1 does not modulate BMP signaling. BIAcore surface plasmon resonance binding assay, TGF-β1/BMP reporter assays, phospho-Smad2 western blot, Smad2/TGFRI knockdown, Src/PKCδ inhibition Experimental cell research High 31302030
2019 CDCP1 promotes Wnt signaling in colorectal cancer by facilitating translocation of β-catenin and E-cadherin to the nucleus; disruption of CDCP1 reduces nuclear/chromatin-associated β-catenin and nuclear E-cadherin, increases their sequestration at the membrane, and disrupts regulation of CRC-promoting genes. Cell fractionation, co-immunoprecipitation, confocal microscopy, immunohistochemistry of patient samples, CDCP1 loss-of-function in vitro and in vivo Oncogene High 31471585
2019 CDCP1 forms homophilic complexes via its extracellular CUB2 domain; deletion of the extracellular region abolishes complex formation and the ability to promote cancer cell migration; recombinant CUB2 domain protein competitively inhibits CDCP1 homophilic complex formation, SFK activation, and cell migration. CDCP1 deletion mutants, recombinant CUB2-MBP fusion protein competitive inhibition, co-immunoprecipitation, SFK activation assays, migration assays in lung adenocarcinoma and pancreatic cells Oncology reports Medium 31524271
2020 Androgen signaling suppresses CDCP1 expression; androgen deprivation combined with PTEN loss upregulates CDCP1, which then activates the SRC/MAPK pathway to promote metastatic prostate cancer progression. Androgen treatment/deprivation, PTEN loss genetic models, CDCP1 expression analysis, SRC/MAPK pathway western blot, in vivo prostate cancer progression models The Journal of clinical investigation High 32250342
2021 Urokinase plasminogen activator (uPA) is the master regulator of CDCP1 proteolysis, acting both by directly cleaving CDCP1 and by activating plasmin (which also cleaves CDCP1); uPA-mediated CDCP1 proteolysis promotes metastasis in preclinical in vivo models; co-expression of uPA and CDCP1 is predictive of poor disease outcome. Substrate-biased activity-based probe (sbABP) incorporating CDCP1 cleavage motif for protease capture/identification, in vitro cleavage assays, in vivo metastasis models, patient data analysis Nature chemical biology High 33859413
2021 CDCP1 on dendritic cells (DCs) regulates IL-6 production via the Syk-MAPK signaling pathway; CDCP1-KO DCs show reduced CAWS-induced IL-6 production associated with impaired Syk-MAPK signaling; CDCP1-KO mice show attenuated coronary and aortic vasculitis in a Kawasaki disease model. CDCP1 knockout mice, DC-specific expression analysis, CAWS stimulation assays, IL-6 ELISA, Syk-MAPK western blot in WT vs. KO DCs Journal of immunology High 34099547
2021 CDCP1 promotes compensatory renal growth downstream of HGF by recruiting Src into lipid rafts to activate STAT3 associated with the HGF receptor Met; activated STAT3 then induces matrix metalloproteinase and mitogenic factor expression; CDCP1 ablation in mice attenuates Met-STAT3 signaling and suppresses compensatory growth after unilateral nephrectomy. CDCP1 siRNA/ablation in canine kidney cells, lipid raft fractionation, Co-IP of Src/STAT3/Met, STAT3 phosphorylation assays, unilateral nephrectomy in CDCP1-ablated mice Life science alliance High 33574034
2022 The two cleaved fragments of CDCP1 remain tightly associated with minimal conformational change after proteolysis; differential phage display generated antibodies that selectively recognize the proteolytic neoepitope of cleaved CDCP1 with no detectable binding to uncleaved form; biochemical and structural characterization confirmed this. Differential phage display, biochemical and biophysical characterization, structural analysis of cleaved vs. uncleaved CDCP1, antibody-drug conjugate/radionuclide/bispecific T cell engager functional studies, syngeneic pancreatic tumor model The Journal of clinical investigation High 35166238
2017 CDCP1 regulates EGF/EGFR-induced cell migration; EGF/EGFR activation upregulates CDCP1 mRNA and protein via the RAS/RAF/MEK/ERK pathway (not Src), and CDCP1 relocates from cell-cell junctions to filopodia; disruption of CDCP1 by silencing or blocking antibody reduces EGF/EGFR-induced migration. CDCP1 silencing, function-blocking antibody, ERK inhibitors, EGF treatment, live-cell imaging of CDCP1 localization, migration assays The Journal of biological chemistry High 22315226
2017 CDCP1 is phosphorylated by Src family kinases and recruits PKCδ through the C2 domain of PKCδ in a phosphotyrosine-dependent manner; a small molecule (glycoconjugated palladium complex Pd-Oqn) inhibits the interaction between PKCδ C2 domain and phosphorylated CDCP1, suppresses PKCδ phosphorylation (but not ERK or AKT), inhibits anchorage-independent growth and invasion in vitro, and reduces peritoneal dissemination and tumor growth in vivo. Cell-free screening, immunoprecipitation assays with PKCδ C2 domain, soft agar colony formation, invasion assays, in vivo peritoneal dissemination and orthotopic xenograft models Cancer science High 28256037
2022 CDCP1 promotes HGF-induced breast cancer cell invasion through a CDCP1-SRC-ARHGEF7-RAC1 pathway; CDCP1 coaccumulates with ARHGEF7, activates SRC, which activates ARHGEF7-RAC1 GTPase signaling, leading to lamellipodia formation and invasion. CDCP1 knockdown, ectopic MET and CDCP1 expression, Rac1 activation assays, ARHGEF7 knockdown, immunofluorescence co-localization of CDCP1 and ARHGEF7, migration/invasion assays The Journal of biological chemistry High 35085554
2022 BRD4 and CBP/p300 transcription cofactors co-regulate CDCP1 gene transcription in castration-resistant prostate cancer; combined knockdown or dual inhibition reduces CDCP1 transcription and downstream PI3K/AKT and SRC/MAPK signaling more effectively than single-protein perturbation. BRD4 and CBP/p300 knockdown (individual and combined), NEO2734 dual bromodomain inhibitor, CDCP1 transcription assays, PI3K/AKT and SRC/MAPK western blot, cell proliferation/metastasis assays Oncogene Medium 35513563
2021 CDCP1 on RPE cells is upregulated by IFN-γ and interacts with CD6 on T cells; CD6 stimulation of CDCP1-expressing (but not CDCP1-knockdown) RPE cells induces stress fiber formation, focal adhesion disruption, tight junction opening, and increased RPE barrier permeability permitting T cell infiltration, contributing to experimental autoimmune uveitis development. CDCP1-KO mice in EAU passive model, CDCP1-KD RPE cells, CD6 stimulation assays, tight junction immunofluorescence, T cell transmigration assays, IFN-γ stimulation JCI insight High 35951427
2021 hsa_circ_0005358 suppresses CDCP1 expression by binding PTBP1 protein via its 215-224 sequence, sequestering PTBP1 and preventing PTBP1 from stabilizing CDCP1 mRNA, thereby reducing CDCP1 protein translation and suppressing cervical cancer metastasis. RNA pull-down assay, mass spectrometry, RNA immunoprecipitation, RNA-sequencing, functional migration/invasion and in vivo metastasis assays Molecular therapy. Nucleic acids High 34976440
2023 CDCP1 knockdown in vascular smooth muscle cells suppresses PDGFRβ/AKT signaling by promoting NEDD4-mediated ubiquitination of PDGFRβ, preventing PDGFRβ binding to clathrin and Rab5, thus inhibiting PDGFRβ endocytosis; CDCP1 thereby regulates VSMC proliferation and migration. CDCP1 knockdown, RNA-seq, Co-IP of PDGFRβ with NEDD4/clathrin/Rab5, ubiquitination assays, immunofluorescence, AKT pathway western blot, in vivo carotid stenosis model PeerJ Medium 40256729
2023 CDCP1 in cardiac fibroblasts (HCFs) is induced by PDGF signaling; CDCP1 knockdown reduces HCF proliferation, decreases AKT phosphorylation, and reduces expression of soluble ST2 (a cardiac fibrosis inducer), implicating CDCP1 in regulating cardiac fibrosis. CDCP1 knockdown in HCFs, PDGF stimulation, AKT phosphorylation western blot, transcriptomic profiling, ST2 expression analysis Circulation research Medium 37800334
2012 Structural requirements for CDCP1/Src-dependent transformation of NIH3T3 cells require intact amino- and carboxy-termini; mutation of any core intracellular tyrosine residue (Y734, Y743, or Y762) abolishes transformation; mutation of palmitoylation motif (C689,690G) strongly reduces transformation; Src binding to CDCP1 via its SH2 domain is not required for transformation, but Src myristoylation is necessary. Retrovirus-mediated co-overexpression of c-Src and CDCP1 in NIH3T3 cells, focus formation assay, systematic mutagenesis of tyrosines and palmitoylation motif, Src domain mutants (SH2-deficient, myristoylation-deficient) PloS one High 23300860
2023 CDCP1 overexpression activates MAPK/ERK pathway signaling in ex vivo urothelial carcinoma organoids from a CDCP1 transgenic mouse model; CDCP1 knockout in UC cell lines reduces MAPK/ERK activity concomitant with reduced proliferation and migration. CDCP1 transgenic mouse organoids, CRISPR/Cas9 CDCP1 knockout, MAPK/ERK western blot, proliferation/migration assays Scientific reports Medium 36593286

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2017 CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation. Proceedings of the National Academy of Sciences of the United States of America 158 28739932
2019 Dynamic m6A mRNA methylation reveals the role of METTL3-m6A-CDCP1 signaling axis in chemical carcinogenesis. Oncogene 155 30796352
2001 Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene 117 11466621
2003 Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 116 12660814
2012 In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling. Oncogene 104 23208492
2011 CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis. Proceedings of the National Academy of Sciences of the United States of America 82 21220330
2017 CD318 is a ligand for CD6. Proceedings of the National Academy of Sciences of the United States of America 81 28760953
2004 CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin. Stem cells (Dayton, Ohio) 66 15153610
2021 The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention. Cancer research 65 33509939
2010 Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta. The Journal of biological chemistry 65 20551327
2014 Oncogenic Ras/ERK signaling activates CDCP1 to promote tumor invasion and metastasis. Molecular cancer research : MCR 62 24939643
2011 Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells. Oncogene 62 22179830
2021 Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nature communications 61 33674603
2009 The cell surface glycoprotein CDCP1 in cancer--insights, opportunities, and challenges. IUBMB life 61 19514048
2013 Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America 56 23378636
2015 Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. Cell reports 54 25892239
2003 CDCP1 is a novel marker for hematopoietic stem cells. Annals of the New York Academy of Sciences 52 12799299
2019 CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin. Oncogene 42 31471585
2006 Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells. The Journal of pathology 40 16823897
2016 CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer. Oncogene 39 26876198
2021 Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer. Cancer research 38 33574093
2012 The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration. The Journal of biological chemistry 38 22315226
2020 CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. The Journal of clinical investigation 37 32250342
2016 Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer. British journal of cancer 37 26882065
2020 Programmable N6-methyladenosine modification of CDCP1 mRNA by RCas9-methyltransferase like 3 conjugates promotes bladder cancer development. Molecular cancer 36 33267838
2023 Metastatic prostate cancer-derived extracellular vesicles facilitate osteoclastogenesis by transferring the CDCP1 protein. Journal of extracellular vesicles 34 36880252
2014 EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface. Oncogene 34 24681947
2016 CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. Oncotarget 33 27626701
2007 Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS letters 33 17335815
2020 Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 32 32341034
2013 Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy. Molecular oncology 32 24055141
2008 The role of membrane microdomains in transmembrane signaling through the epithelial glycoprotein Gp140/CDCP1. Biochimica et biophysica acta 32 18269919
2017 ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis. Oncotarget 31 28537886
2013 CDCP1 regulates the function of MT1-MMP and invadopodia-mediated invasion of cancer cells. Molecular cancer research : MCR 31 23439492
2011 Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734. The Journal of biological chemistry 31 21994943
2022 Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers. The Journal of clinical investigation 30 35166238
2020 Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma. Theranostics 28 32226543
2021 Methylation of microRNA-338-5p by EED promotes METTL3-mediated translation of oncogene CDCP1 in gastric cancer. Aging 27 33882457
2012 KAI1 suppresses HIF-1α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer. BMC cancer 27 22390300
2015 HIF-2α regulates CDCP1 to promote PKCδ-mediated migration in hepatocellular carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 25 26307391
2020 Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer. Theranostics 24 32104500
2018 The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer. BMC cancer 24 29792166
2023 Identification and multicentric validation of soluble CDCP1 as a robust serological biomarker for risk stratification of NASH in obese Chinese. Cell reports. Medicine 21 37918406
2022 AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer. Scientific reports 21 35643725
2022 Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer. Oncogene 20 35513563
2021 Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1. Nature chemical biology 20 33859413
2021 CDCP1 on Dendritic Cells Contributes to the Development of a Model of Kawasaki Disease. Journal of immunology (Baltimore, Md. : 1950) 20 34099547
2022 CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clinical cancer research : an official journal of the American Association for Cancer Research 19 35604681
2020 Increased Plasma Levels of the Co-stimulatory Proteins CDCP1 and SLAMF1 in Patients With Autoimmune Endocrine Diseases. Frontiers in immunology 19 32983115
2018 Hepatic stem cells with self-renewal and liver repopulation potential are harbored in CDCP1-positive subpopulations of human fetal liver cells. Stem cell research & therapy 19 29402311
2018 Regulation of inside-out β1-integrin activation by CDCP1. Oncogene 18 29511352
2018 FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation. Oncogene 18 29973690
2016 New crossroads for potential therapeutic intervention in cancer - intersections between CDCP1, EGFR family members and downstream signaling pathways. Oncoscience 18 26973855
2015 Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer. Oncotarget 18 26497208
2013 Stratum basale keratinocyte expression of the cell-surface glycoprotein CDCP1 during epidermogenesis and its role in keratinocyte migration. The British journal of dermatology 18 23121233
2023 Myocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of CDCP1 and Cardiac Fibrosis. Circulation research 17 37800334
2021 hsa_circ_0005358 suppresses cervical cancer metastasis by interacting with PTBP1 protein to destabilize CDCP1 mRNA. Molecular therapy. Nucleic acids 17 34976440
2017 Novel small molecule inhibiting CDCP1-PKCδ pathway reduces tumor metastasis and proliferation. Cancer science 17 28256037
2014 CDCP1 identifies a CD146 negative subset of marrow fibroblasts involved with cytokine production. PloS one 16 25275584
2010 CD318/CUB-domain-containing protein 1 expression on cord blood hematopoietic progenitors. Experimental and therapeutic medicine 14 22993567
2022 CDCP1 regulates retinal pigmented epithelial barrier integrity for the development of experimental autoimmune uveitis. JCI insight 13 35951427
2019 CUB domain-containing protein 1 (CDCP1) binds transforming growth factor beta family members and increase TGF-β1 signaling pathway. Experimental cell research 13 31302030
2011 Infrared spectral signatures of CDCP1-induced effects in colon carcinoma cells. The Analyst 13 22034616
2022 CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy. Theranostics 12 36276654
2017 Development of an enzyme-linked immunosorbent assay for detection of CDCP1 shed from the cell surface and present in colorectal cancer serum specimens. Journal of pharmaceutical and biomedical analysis 12 28279929
2014 CUB domain containing protein 1 (CDCP1) modulates adhesion and motility in colon cancer cells. BMC cancer 12 25301083
2012 Structural requirements for cub domain containing protein 1 (CDCP1) and Src dependent cell transformation. PloS one 12 23300860
2022 SRC kinase activator CDCP1 promotes hepatocyte growth factor-induced cell migration/invasion of a subset of breast cancer cells. The Journal of biological chemistry 11 35085554
2022 Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma. Cancer cell international 11 35410293
2022 CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer. Clinical and experimental medicine 11 36495368
2024 Targeting CDCP1 boost CD8+ T cells-mediated cytotoxicity in cervical cancer via the JAK/STAT signaling pathway. Journal for immunotherapy of cancer 10 39455095
2023 Ascites-derived CDCP1+ extracellular vesicles subcluster as a novel biomarker and therapeutic target for ovarian cancer. Frontiers in oncology 10 37469398
2017 Inhibition of pulmonary carcinoma proliferation or metastasis of miR-218 via down-regulating CDCP1 expression. European review for medical and pharmacological sciences 10 28429357
2011 Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration. Biochemical and biophysical research communications 10 21945930
2022 CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer. Life sciences 9 35504333
2021 CDCP1 promotes compensatory renal growth by integrating Src and Met signaling. Life science alliance 9 33574034
2015 The tyrosine phosphatase SHP2 associates with CUB domain-containing protein-1 (CDCP1), regulating its expression at the cell surface in a phosphorylation-dependent manner. PloS one 9 25876044
2006 Role of DNA methylation for expression of novel stem cell marker CDCP1 in hematopoietic cells. Leukemia 9 16926850
2023 Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 8 36648492
2023 Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging. iScience 8 36866248
2020 The emerging role of the MiR-1272-ADAM9-CDCP1 signaling pathway in the progression of glioma. Aging 8 33260155
2015 The role of CDCP1 (CUB domain-containing protein 1) and ADAM12 (a disintegrin and metalloproteinase 12) in ovarian cancer. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 8 26214617
2023 Inhibition of CDCP1 by 8-isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment. Molecular oncology 7 37013960
2019 Effect of NLK on the proliferation and invasion of laryngeal carcinoma cells by regulating CDCP1. European review for medical and pharmacological sciences 7 31364124
2024 The CD318/CD6 axis limits type 1 diabetes islet autoantigen-specific human T cell activation. Journal of autoimmunity 6 38642507
2018 CUB Domain-containing Protein 1 (CDCP1) Is Down-regulated by Active Hexose-correlated Compound in Human Pancreatic Cancer Cells. Anticancer research 6 30396925
2023 CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression. Scientific reports 5 36593286
2021 Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer. Molecular pharmaceutics 5 34448393
2018 Evidence that cell surface localization of serine protease activity facilitates cleavage of the protease activated receptor CDCP1. Biological chemistry 5 29447112
2021 Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer. Contrast media & molecular imaging 4 34621145
2019 Homophilic complex formation of CDCP1 via the extracellular CUB2 domain facilitates SFK activation and promotes cancer cell migration. Oncology reports 4 31524271
2023 CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma. PloS one 3 36862682
2023 Erratum: Mechanistic insights into CDCP1 clustering on non-small-cell lung cancer membranes revealed by super-resolution fluorescent imaging. iScience 3 36942052
2021 Loss of CDCP1 triggers FAK activation in detached prostate cancer cells. American journal of clinical and experimental urology 3 34541033
2025 Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2- Breast Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 2 39869307
2025 CDCP1 knockdown suppresses PDGFRβ/AKT pathway-mediated vascular smooth muscle cell proliferation by inhibiting PDGFRβ endocytosis. PeerJ 2 40256729
2025 Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines. Frontiers in immunology 2 40391211
2025 CDCP1 promotes the malignant phenotypes of nasopharyngeal carcinoma via the Wnt/β-catenin signaling pathway. BMC biotechnology 2 40624715
2022 CDCP1-targeted nanoparticles encapsulating phase-shift perfluorohexan for molecular US imaging in vitro. Clinical hemorheology and microcirculation 2 33185589
2022 Cleaved CDCP1 marks the spot: a neoepitope for RAS-driven cancers. The Journal of clinical investigation 2 35166242